EMERALD-3: Phase III trial of IMFINZI ® (durvalumab) in combination with IMJUDO ® (tremelimumab-actl), with or without lenvatinib, and transarterial chemoembolization (TACE) in patients with ...
Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented –ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced ...
Twenty-three abstracts will highlight the versatility and strength of Genmab’s portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral ...
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
Eli Lilly and Company , the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and ...
aHealth Protection Research Unit in Emerging and Zoonotic Infections, Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary, and Ecological Sciences, ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present new data across its oncology portfolio at the 2026 American Society of Clinical Oncology ...
Granite quarrying in Chittoor, Andhra Pradesh, raises concerns over illegal mining, environmental damage, and the plight of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results